SCHEMBL25846131

SCHEMBL25846131

Cn1c2c(c3cccnc31)CCCCC2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 1/20 0.48
CRBN Q96SW2 1/20 0.48
ALOX5 P09917 1/20 0.44
PTGS1 P23219 1/20 0.44
PTGS2 P35354 1/20 0.44
FEN1 P39748 1/20 0.42
HTR2C P28335 4/20 0.39
HTR2A P28223 3/20 0.39
CHRM2 P08172 1/20 0.39
HTR1A P08908 1/20 0.39
CHRM5 P08912 1/20 0.39
ADRA2A P08913 1/20 0.39
DRD2 P14416 1/20 0.39
ADRA2B P18089 1/20 0.39
ADRA2C P18825 1/20 0.39
CHRM3 P20309 1/20 0.39
DRD4 P21917 1/20 0.39
SLC6A2 P23975 1/20 0.39
HRH2 P25021 1/20 0.39
AVPR2 P30518 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30339398 0.83 CYP1A2 (0.44) DDB1CRBNFEN1HTR2CHTR2A
SCHEMBL24101726 0.83 CYP1A2 (0.44) DDB1CRBNFEN1HTR2CHTR2A
SCHEMBL30339574 0.81 HTR2A (0.59) DDB1CRBNFEN1HTR2CHTR2A
SCHEMBL24101662 0.81 HTR2A (0.59) DDB1CRBNFEN1HTR2CHTR2A
SCHEMBL25467584 0.78 DDB1 (0.46) DDB1CRBNHTR2CHTR2ACA1
SCHEMBL19271273 0.78 DDB1 (0.46) DDB1CRBNHTR2CHTR2ACHRM2
SCHEMBL24110445 0.78 HTR6 (0.55) DDB1CRBNHTR2CHTR2ACHRM2
SCHEMBL25846134 0.78 MCHR1 (0.49) DDB1CRBNFEN1HRH1HTR6
SCHEMBL21114798 0.77 HTR2A (0.47) FEN1HTR2CHTR2AKDM4EALOX15
SCHEMBL968115 0.77 HTR2A (0.47) DDB1CRBNFEN1HTR2CHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230227453-A1 TRICYCLIC PSYCHOPLASTOGENS AND USES THEREOF DELIX THERAPEUTICS, INC. 2023-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230227453-A1 TRICYCLIC PSYCHOPLASTOGENS AND USES THEREOF GAP43, GRIN2A, GRIN2C DDB1 2175/4885CRBN 1655/4885ALOX5 870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.